Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
03. März 2021 16:05 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Progress
25. Februar 2021 16:05 ET
|
Translate Bio, Inc.
-- Additional interim data expected in early Q2 from Phase 1/2 clinical trial of MRT5005 for the treatment of cystic fibrosis (CF) -- -- Two infectious disease mRNA vaccine programs expected to enter...
Translate Bio to Present at the SVB Leerink Virtual 10th Annual Global Healthcare Conference
18. Februar 2021 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
03. Februar 2021 16:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Timing of Interim Results from mRNA Therapeutic Clinical Trial in Patients with Cystic Fibrosis; Data Expected in Early Q2 2021
07. Januar 2021 07:30 ET
|
Translate Bio, Inc.
-- MRT5005 is the first clinical-stage mRNA therapeutic with nebulized delivery to the lung and first to be administered in multiple doses for the treatment of a chronic genetic disease -- --...
Translate Bio Announces Departure of Chief Financial Officer
22. Dezember 2020 16:20 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio to Participate in Upcoming Investor Conferences
12. November 2020 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Third Quarter 2020 Financial Results and Reviews Recent Progress
05. November 2020 16:21 ET
|
Translate Bio, Inc.
-- Advances Phase 1/2 clinical trial of MRT5005 for the treatment of cystic fibrosis (CF) with resumption of COVID-impacted enrollment and dosing -- -- Presented promising preclinical data at NACFC...
Sanofi and Translate Bio mRNA COVID-19 Vaccine Candidate Induced High Antibody Levels in Preclinical Studies
15. Oktober 2020 08:00 ET
|
Translate Bio, Inc.
-- mRNA-based vaccine candidate MRT5500 induced potent neutralizing antibodies against SARS-CoV-2 in preclinical studies -- -- Two doses of MRT5500 induced neutralizing antibody levels significantly...
Translate Bio Highlights mRNA Platform Potential for the Treatment of Cystic Fibrosis (CF) at the 34th Annual North American Cystic Fibrosis Conference
07. Oktober 2020 16:05 ET
|
Translate Bio, Inc.
-- Lead candidate MRT5005 leverages Translate Bio’s proprietary LNP and mRNA platform and is the only clinical-stage mRNA therapeutic in development for the treatment of CF -- -- Second CF program,...